Shares of Sientra Inc. (NASDAQ:SIEN) shot up 14.5% on Tuesday . The company traded as high as $8.41 and last traded at $8.14, with a volume of 888,624 shares traded. The stock had previously closed at $7.11.

A number of brokerages have recently weighed in on SIEN. Zacks Investment Research lowered shares of Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, April 19th. William Blair began coverage on shares of Sientra in a research note on Wednesday. They issued a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Sientra currently has a consensus rating of “Hold” and an average target price of $28.50.

The firm’s market cap is $139.88 million. The company has a 50 day moving average price of $7.04 and a 200-day moving average price of $7.19.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.05. The firm had revenue of $6.20 million for the quarter, compared to the consensus estimate of $4.80 million. Analysts predict that Sientra Inc. will post ($2.33) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Sientra stock. Globeflex Capital L P acquired a new position in shares of Sientra Inc. (NASDAQ:SIEN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 181,200 shares of the company’s stock, valued at approximately $1,073,000. Globeflex Capital L P owned 1.01% of Sientra as of its most recent filing with the SEC.

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.